Patent intelligence · US
US 2017354716
Novel Polymeric hGH Prodrugs
Novel Polymeric hGH Prodrugs
Patent details — US 2017354716
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 14, 2017
- Expiration
- Dec 9, 2037
- CPC classes
- A61K 9/ 08 A I, A61K 38/ 27 A I, A61K 47/ 12 A I, A61K 47/ 20 A I
Quick answer
US 2017354716 (Novel Polymeric hGH Prodrugs) is held by ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S [DK]. Status: granted. Granted Dec 14, 2017. Expires Dec 9, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 08 A I, A61K 38/ 27 A I, A61K 47/ 12 A I, A61K 47/ 20 A I, A61K 47/ 26 A I, A61K 47/ 60 A I
More from ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S [DK]
Related pharmaceutical patents in our USPTO index.
-
US 2025295738
Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily Somatropin
granted -
CA 3131817
FORMES POSOLOGIQUES D'HORMONE DE CROISSANCE A ACTION PROLONGEE AYANT UNE EFFICACITE SUPERIEURE A UNE DOSE DE SOMATROPINE QUOTIDIENNE
granted -
US 2017312342
Long-Acting Growth Hormone Dosage Forms
granted -
US 2017056477
Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier
granted -
US 2016206702
PEGylated Recombinant Human Growth Hormone Compounds
granted
Frequently asked questions
What is US patent 2017354716?
US 2017354716 (Novel Polymeric hGH Prodrugs) is held by ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S [DK]. Status: granted. Granted Dec 14, 2017. Expires Dec 9, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2017354716?
ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S [DK] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 2017354716 expire?
Our index shows an expiration date of Dec 9, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.